Autopsy report · NCT01479231

Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis

“Souces of funding have been terminated”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1, Phase 2

Sponsor

Mayo Clinic

Sponsor type

University, hospital or other

Conditions

Gastroesophageal Reflux Disease; Eosinophilic Esophagitis; Dysphagia

Interventions

dexlansoprazole

Participants

0

Trials that died the same way

• The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations
  “Funding was terminated” (91% match in meaning)
• Angiotensin 1-7 in Obesity Hypertension
  “Funding terminated” (89% match in meaning)
• Lusedra (Fospropofol Disodium) for Minimal to Moderate Sedation for Regional Anesthesia Block Prior to Orthopedic Surgery
  “Funding terminated by funding source.” (86% match in meaning)
• Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
  “Terminated due to loss of funding” (86% match in meaning)
• Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
  “Terminated due to loss in funding” (85% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.